Anti-CD3 antibody treatment induces hypoglycemia and super tolerance to glucose challenge in mice through enhancing glucose consumption by activated lymphocytes

Journal of Immunology Research

Volumn 2014, Issue , 2014, Pages

  Xia, Chang Qing ^a,b   Chernatynskaya, Anna V ^b   Looney, Benjamin ^b   Wan, Suigui ^a   Clare Salzler, Michael J ^b  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; C PEPTIDE; CD3 ANTIGEN; CYTOKINE; GLUCOSE; GLUCOSE BLOOD LEVEL; MONOCLONAL ANTIBODY;

ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIA; IMMUNOLOGY; KNOCKOUT MOUSE; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; METABOLISM; MOUSE; NONOBESE DIABETIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; BIOLOGICAL TRANSPORT; BLOOD GLUCOSE; C-PEPTIDE; CYTOKINES; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE; GLUCOSE TOLERANCE TEST; HYPOGLYCEMIA; INFLAMMATION MEDIATORS; LYMPHOCYTE ACTIVATION; LYMPHOCYTES; MICE; MICE, INBRED NOD; MICE, KNOCKOUT;

EID: 84898688371     PISSN: 23148861     EISSN: 23147156     Source Type: Journal    
DOI: 10.1155/2014/326708     Document Type: Article

References (21)

1. Yu X.-Z., Levin S. D., Madrenas J., Anasetti C., Lck is required for activation-induced T cell death after TCR ligation with partial agonists. Journal of Immunology 2004 172 3 1437 1443 2-s2.0-1642526001
2. Fife B. T., Guleria I., Bupp M. G., Eagar T. N., Tang Q., Bour-Jordan H., Yagita H., Azuma M., Sayegh M. H., Bluestone J. A., Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. The Journal of Experimental Medicine 2006 203 12 2737 2747 2-s2.0-33751552197 10.1084/jem.20061577
3. Penaranda C., Tang Q., Bluestone J. A., Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. Journal of Immunology 2011 187 4 2015 2022 2-s2.0-80051931752 10.4049/jimmunol.1100713
4. You S., Leforban B., Garcia C., Bach J.-F., Bluestone J. A., Chatenoud L., Adaptive TGF- β -dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proceedings of the National Academy of Sciences of the United States of America 2007 104 15 6335 6340 2-s2.0-34547204632 10.1073/pnas.0701171104
5. Bresson D., Togher L., Rodrigo E., Chen Y., Bluestone J. A., Herold K. C., Von Herrath M., Anti-CD3 and nasal proinsulin combination therapy enhances remission from recentonset autoimmune diabetes by inducing Tregs. The Journal of Clinical Investigation 2006 116 5 1371 1381 2-s2.0-33646392755 10.1172/JCI27191
6. Perruche S., Zhang P., Liu Y., Saas P., Bluestone J. A., Chen W., CD3-specific antibody-induced immune tolerance involves transforming growth factor- β from phagocytes digesting apoptotic T cells. Nature Medicine 2008 14 5 528 535 2-s2.0-43249097073 10.1038/nm1749
7. Li N., Zhao D., Kirschbaum M., Zhang C., Lin C.-L., Todorov I., Kandeel F., Forman S., Zeng D., HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proceedings of the National Academy of Sciences of the United States of America 2008 105 12 4796 4801 2-s2.0-42449130607 10.1073/pnas.0712051105
8. Alegre M., Vandenabeele P., Flamand V., Moser M., Leo O., Abramowicz D., Urbain J., Fiers W., Goldman M., Hypothermia and hypoglycemia induced by anti-CD3 monoclonal antibody in mice: role of tumor necrosis factor. European Journal of Immunology 1990 20 3 707 710 2-s2.0-0025361331
9. Alegre M.-A., Vandenabeele P., Depierreux M., Florquin S., Deschodt-Lanckman M., Flamand V., Moser M., Leo O., Urbain J., Fiers W., Goldman M., Cytokine release syndrome induced by the 145-2C11 anti-CD3 monoclonal antibody in mice: prevention by high doses of methylprednisolone. Journal of Immunology 1991 146 4 1184 1191 2-s2.0-0026101720
10. Koya V., Lu S., Sun Y.-P., Purich D. L., Atkinson M. A., Li S.-W., Yang L.-J., Reversal of streptozotocin-induced diabetes in mice by cellular transduction with recombinant pancreatic transcription factor pancreatic duodenal homeobox-1 a novel protein transduction domain-based therapy. Diabetes 2008 57 3 757 769 2-s2.0-40949136580 10.2337/db07-1441
11. Ablamunits V., Henegariu O., Hansen J. B., Opare-Addo L., Preston-Hurlburt P., Santamaria P., Mandrup-Poulsen T., Herold K. C., Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012 61 1 145 154 2-s2.0-84555188737 10.2337/db11-1033
12. Matthys P., Dillen C., Proost P., Heremans H., Van Damme J., Billiau A., Modification of the anti-CD3-induced cytokine release syndrome by anti-interferon- γ or anti-interleukin-6 antibody treatment: protective effects and biphasic changes in blood cytokine. European Journal of Immunology 1993 23 9 2209 2216 2-s2.0-0027291984
13. Marko A. J., Miller R. A., Kelman A., Frauwirth K. A., Induction of glucose metabolism in stimulated T lymphocytes is regulated by mitogen-activated protein kinase signaling. PLoS ONE 2010 5 11 2-s2.0-78649737749 10.1371/journal.pone.0015425 e15425
14. Sherry N., Hagopian W., Ludvigsson J., Jain S. M., Wahlen J., Ferry R. J. Jr., Bode B., Aronoff S., Holland C., Carlin D., King K. L., Wilder R. L., Pillemer S., Bonvini E., Johnson S., Stein K. E., Koenig S., Herold K. C., Daifotis A. G., Teplizumab for treatment of type 1 diabetes (Proté gé study): 1-year results from a randomised, placebo-controlled trial. The Lancet 2011 378 9790 487 497 2-s2.0-80051471700 10.1016/S0140-6736(11)60931- 8
15. Herold K. C., Gitelman S. E., Masharani U., Hagopian W., Bisikirska B., Donaldson D., Rother K., Diamond B., Harlan D. M., Bluestone J. A., A single course of anti-CD3 monoclonal antibody hOKT3 γ 1(ala-ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005 54 6 1763 1769 2-s2.0-20044375937 10.2337/diabetes.54.6.1763
16. Herold K. C., Hagopian W., Auger J. A., Poumian-Ruiz E., Taylor L., Donaldson D., Gitelman S. E., Harlan D. M., Xu D., Zivin R. A., Bluestone J. A., Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. The New England Journal of Medicine 2002 346 22 1692 1698 2-s2.0-0037198420 10.1056/NEJMoa012864
17. Popmihajlov Z., Xu D., Morgan H., Milligan Z., Smith K. A., Conditional IL-2 gene deletion: consequences for T cell proliferation. Frontiers in Immunology 2012 3, article 102
18. Wang R., Dillon C. P., Shi L. Z., Milasta S., Carter R., Finkelstein D., McCormick L. L., Fitzgerald P., Chi H., Munger J., Green D. R., The transcription factor Myc controls metabolic reprogramming upon T lymphocyte activation. Immunity 2011 35 6 871 882 2-s2.0-84255199079 10.1016/j.immuni.2011. 09.021
19. Michalek R. D., Gerriets V. A., Jacobs S. R., Macintyre A. N., MacIver N. J., Mason E. F., Sullivan S. A., Nichols A. G., Rathmell J. C., Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets. Journal of Immunology 2011 186 6 3299 3303 2-s2.0-79953172571 10.4049/jimmunol.1003613
20. Maratou E., Dimitriadis G., Kollias A., Boutati E., Lambadiari V., Mitrou P., Raptis S. A., Glucose transporter expression on the plasma membrane of resting and activated white blood cells. European Journal of Clinical Investigation 2007 37 4 282 290 2-s2.0-33947308147 10.1111/j.1365-2362.2007. 01786.x
21. Chakrabarti R., Jung C. Y., Lee T.-P., Liu H., Mookerjee B. K., Changes in glucose transport and transporter isoforms during the activation of human peripheral blood lymphocytes by phytohemagglutinin. Journal of Immunology 1994 152 6 2660 2668 2-s2.0-0028231378